PDS Biotechnology develops immunotherapies that aim to treat cancer and to prevent infectious diseases. PDSB reports earnings on Thu, Nov 12, 2026. In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | B. Riley Securities | Reiterated | Buy | |
| Sep 8 | HC Wainwright & Co. | Target lowered | Buy | |
| Aug 26 | HC Wainwright & Co. | Reiterated | Buy | |
| Aug 13 | HC Wainwright & Co. | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in PDSB in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PDSB is in one of them and how their past PDSB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PDSB in an article yet. Here's the latest on the wider market.
About PDS Biotechnology
PDS Biotechnology is a clinical stage immunotherapy company based in Princeton, New Jersey. It is developing cancer treatments built on its Versamune platform, including a combination with an interleukin 12 antibody drug conjugate, and an Infectimune T cell activator for preventive vaccines against infectious agents. The Versamune platform is a lipid nanoparticle designed to stimulate the immune system's killer and helper T cells. Its investigational products are aimed at patients with cancer and at preventive vaccines for infectious diseases.
- Headquarters
- Princeton, NJ